Home » Newsletters » BioWorld Science

BioWorld Science

March 25, 2013

View Archived Issues

A novel potential therapy for the treatment of stress-related autoimmune skin disease

Phase III trial of arbaclofen placarbil ongoing in patients with MS-related spasticity

BreastPRS as a new prognostic panel for breast cancer

GGF2 well tolerated in patients with HF at doses up to 0.75 mg/kg

Phase I trial of PD vaccine candidate PD-01A under way

Teriparatide as the first anabolic therapy for osteogenesis imperfecta

Amakem presents novel ROCK inhibitors

Bayer presents new agents for cardiovascular disorders

Anacor Pharmaceuticals reports results from phase II AN-2728 study

Cancer research institutions collaborate with Janssen to discover multiple myeloma drug

Astellas enters agreements to research new anti-dengue virus drugs

Blueprint Medicines enters oncology collaboration

ChromoTek licenses Chromobody Technology to Bayer

Guerbet announces FDA approval for Dotarem

NDA submitted for brentuximab vedotin in Japan

Updated results from ALSYMPCA trial show survival benefit

GlaxoSmithKline designs new RORgamma modulators

Novel antifungal agents presented by Toyama Chemical and Taisho

Santhera Pharmaceuticals withdraws MAA for Raxone

Metabolex patents new GPBA receptor agonists

CHMP issues positive opinion on HyQvia

Stribild gets positive opinion in Europe

FDA approves AdreView to evaluate cardiac risk in heart failure patients

Cerulean's phase IIb study of CRLX-101 in NSCLC does not meet endpoint

European CHMP recommends approval of Aubagio for relapsing-remitting MS

EMA committee recommends approval of ponatinib for two cancer indications

CHMP recommends European approval of Biogen Idec's Tecfidera

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
DEE-lightful: Praxis’ phase II results allow stock to flex its muscle
BioWorld
Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...